Study finds lecanemab modestly slowed disease's inevitable worsening, but it remained unclear how much of a difference it would make in patients' lives.Experts have welcomed full data showing an experimental drug can slow cognitive decline in Alzheimer's patients, but warned improvements were comparatively small and said it remained unclear how much difference it might make in people's lives.
#people #united-states #researchers #temporarily #improvements #independently #side-effects #asymptomatic #older-adults #early-january
[
add
]
[
|
|
...
]